Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control
Comparative Efficacy and Safety of Multi-Type Photolithography Flat Microstructure Spectacle Lenses Versus Spectacle Lenses With Aspherical Lenslets for Myopia Control in Chinese Children: A 12-Month Randomized Controlled Trial
1 other identifier
interventional
255
1 country
1
Brief Summary
The goal of this clinical trial is to learn if photolithographic flat microstructure lenses work to prevent myopia in children. It will also learn about the safety of different designs of photolithographic flat microstructure lenses. The main questions it aims to answer are: Are photolithography flat microstructure lenses effective and safe in preventing myopia in children? Does the depth of tinted lenses affect visual quality? Researchers will compare photolithography flat microstructure lenses to a spectacle lenses with aspherical lenslets to see if photolithography flat microstructure lenses works to prevent myopia in children. Participants will: Wear photolithography flat microstructure lenses or Spectacle Lenses with Aspherical Lenslets more than 8H per day for 1 year. Visit the clinic once every 3 months for checkups and tests.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 1, 2026
CompletedStudy Start
First participant enrolled
April 15, 2026
CompletedFirst Posted
Study publicly available on registry
April 17, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
April 17, 2026
April 1, 2026
1.5 years
April 1, 2026
April 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Use 1% cyclopentolate hydrochloride eye drops (Cyclogyl) for cycloplegia and compare the difference in Sphere equivalent refractive changes over 12 months.
Computerized refractometer testing, The formula for calculating sphere equivalent power: sphere power + 0.5 \* cylinder power
From enrollment to the end of treatment at 12 month
Secondary Outcomes (1)
Difference in 12-month axial length (AL, mm) from baseline
From enrollment to the end of treatment at 12 month
Study Arms (5)
PPML(multi-point defocus design, non-fading, Nuo Tong)
EXPERIMENTALThe group wears photolithography plano microstructure lenses (PPML) with a multi-point defocus design, manufactured by Nuo Tong, which feature a non-fading optical property.
PPML (multi-point defocus design, color, light transmittance 55% after photochromism, Nuo Tong)
EXPERIMENTALPPML (Photolithography Plano Microstructure Lenses) incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 55% post-activation.
PPML (multi-point defocus design, color, light transmittance 35% after photochromism, Nuo Tong)
EXPERIMENTALPPML (Photolithography Plano Microstructure Lenses) incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 35% post-activation.
PPML (designed to reduce contrast, non-fading, Nuo Tong)
EXPERIMENTALPPML (Photolithography Plano Microstructure Lenses), designed by Nuo Tong to reduce contrast sensitivity and featuring a non-fading optical property
Plano microstructure lenses (multi-point defocus design,Aspherical Lenslets, Essilor Stellest)
ACTIVE COMPARATORPlano microstructure lenses featuring multi-point defocus design with aspherical lenslets (Essilor Stellest)
Interventions
wearing Photolithography Plano Microstructure Lenses designed by Nuo Tong to reduce contrast sensitivity and featuring a non-fading optical property for more than 8 hours
Wearing Photolithography Plano Microstructure Lenses incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 55% post-activation for more than 8 hours.
Wearing Photolithography Plano Microstructure Lenses incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 35% post-activation for more than 8 hours.
wearing photolithography plano microstructure lenses (PPML) with a multi-point defocus design, manufactured by Nuo Tong, which feature a non-fading optical property for more than 8 hours a day.
wearing plano microstructure lenses featuring multi-point defocus design with aspherical lenslets (Essilor Stellest) for more than 8 hours.
Eligibility Criteria
You may qualify if:
- Age: 6 years ≤ age ≤ 8 years (calculated based on the informed consent date);
- The spherical equivalent (SE) of both eyes is 0D to +1.00D (inclusive of boundary values) after cycloplegia;
- Astigmatism: Cylindrical power of both eyes ≤ 1.00D;
- Anisometropia: Difference in spherical equivalent between both eyes ≤ 1.00D;
- Corrected visual acuity: Best corrected visual acuity (BCVA) of both eyes ≥ 1.0 (decimal notation, 5m);
- General health status: No systemic syndromes that affect ocular development; no long-term use of growth hormone, corticosteroids, or antiepileptic drugs;
- Previous intervention: No use of any myopia control methods within the past 3 months, including but not limited to: multifocal glasses, atropine eye drops, red light therapy, acupuncture, etc.
- Compliance with spectacle wear: Parents ensure that the child wears glasses for ≥8 hours per day;
- Follow-up capability: Ability to attend scheduled follow-ups for 12 months (4 visits in total);
- Informed consent from guardian: Legal guardian signs the informed consent form; children also sign the assent form.
You may not qualify if:
- History or presence of glaucoma, corneal disease, or other ocular organic disease, or acute or chronic ocular inflammation;
- Combined with systemic major diseases, mental diseases, or systemic collagen metabolism diseases;
- Used any myopia intervention drugs or devices in the past 3 months;
- Those who have participated in other similar clinical studies in the past 3 months;
- Diagnosis of amblyopia, constant strabismus, and other congenital eye diseases;
- Those who are allergic to the lens material or products related to the study;
- Allergy to mydriatic agents and related ophthalmic medications;
- Allergic to photochromic materials or related dyes; taking photosensitizing drugs; suffering from photo-induced skin or neurological disorders;
- Unable to understand the study content or unable to cooperate with the follow-up;
- Other reasons why the research doctor believes the patient is not suitable for the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai Eye Disease Prevention and treatment Center
Shanghai, 200336, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 1, 2026
First Posted
April 17, 2026
Study Start
April 15, 2026
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
April 17, 2026
Record last verified: 2026-04